PT934309E - Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos - Google Patents

Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos

Info

Publication number
PT934309E
PT934309E PT97929240T PT97929240T PT934309E PT 934309 E PT934309 E PT 934309E PT 97929240 T PT97929240 T PT 97929240T PT 97929240 T PT97929240 T PT 97929240T PT 934309 E PT934309 E PT 934309E
Authority
PT
Portugal
Prior art keywords
citostatic
alcano
amides
new pyridyl
immunosupressive agents
Prior art date
Application number
PT97929240T
Other languages
English (en)
Portuguese (pt)
Inventor
Seibel Prof Dr Klaus
Loser Dr Roland
Reiter Dr Friedemann
Elfi Biedermann
Max Hasmann
Benno Rattel
Barbara Schein
Klaus Vogt
Original Assignee
Fujisawa Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Deutschland Gmbh filed Critical Fujisawa Deutschland Gmbh
Publication of PT934309E publication Critical patent/PT934309E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97929240T 1996-06-20 1997-06-20 Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos PT934309E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19624704A DE19624704A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalkansäureamide

Publications (1)

Publication Number Publication Date
PT934309E true PT934309E (pt) 2002-12-31

Family

ID=7797525

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97929240T PT934309E (pt) 1996-06-20 1997-06-20 Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos

Country Status (11)

Country Link
US (3) US6444823B1 (cg-RX-API-DMAC10.html)
EP (1) EP0934309B1 (cg-RX-API-DMAC10.html)
JP (1) JP4225571B2 (cg-RX-API-DMAC10.html)
AT (1) ATE223912T1 (cg-RX-API-DMAC10.html)
AU (1) AU3342097A (cg-RX-API-DMAC10.html)
DE (2) DE19624704A1 (cg-RX-API-DMAC10.html)
DK (1) DK0934309T3 (cg-RX-API-DMAC10.html)
ES (1) ES2178779T3 (cg-RX-API-DMAC10.html)
PT (1) PT934309E (cg-RX-API-DMAC10.html)
WO (1) WO1997048695A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA975439B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE19908483A1 (de) * 1999-02-26 2000-10-05 Klinge Co Chem Pharm Fab Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
US6172040B1 (en) * 1999-05-28 2001-01-09 A. Satyanarayan Naidu Immobilized lactoferrin antimicrobial agents and the use thereof
ES2527688T3 (es) * 2000-09-29 2015-01-28 Glaxo Group Limited Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2601508C (en) 2005-03-17 2012-01-03 Pfizer, Inc. Cyclopropanecarboxamide derivatives
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007084394A2 (en) * 2006-01-17 2007-07-26 Merck & Co., Inc. 2,5 diaza-bicyclo[2.2.1]heptane derivatives as calcium channel blockers
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
WO2010114907A1 (en) * 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
JP2012533530A (ja) 2009-07-17 2012-12-27 トポターゲット・アクティーゼルスカブ ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法
US9676721B2 (en) 2010-09-03 2017-06-13 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
MX347889B (es) 2010-09-03 2017-05-17 Forma Tm Llc * Compuestos y composiciones novedosos para la inhibición de nampt.
WO2012031196A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
KR20140027366A (ko) 2011-05-04 2014-03-06 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 신규 화합물 및 조성물
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
CN109776494B (zh) * 2018-12-25 2021-06-18 中国人民解放军第二军医大学 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
JPS57136518A (en) * 1981-02-18 1982-08-23 Eisai Co Ltd Immunoregulator
US5326772A (en) * 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) * 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) * 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0401256B1 (de) 1988-02-19 1993-05-26 Byk Gulden Lomberg Chemische Fabrik GmbH Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) * 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
AU7652391A (en) * 1990-04-10 1991-10-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridine esters
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4020570A1 (de) * 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
EP0471236B1 (en) * 1990-07-30 1995-03-15 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their use
US5229400A (en) * 1990-10-05 1993-07-20 Ajinomoto Co., Inc. Piperidine compounds and their use as antiarrhythmic agents
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE152102T1 (de) * 1991-05-10 1997-05-15 Takeda Chemical Industries Ltd Pyridinderivate, deren herstellung und anwendung
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
ES2164717T3 (es) 1993-10-15 2002-03-01 Schering Corp Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
EP0750496A1 (en) 1994-03-14 1997-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

Also Published As

Publication number Publication date
DK0934309T3 (da) 2002-12-23
WO1997048695A1 (en) 1997-12-24
EP0934309A1 (en) 1999-08-11
US7276524B2 (en) 2007-10-02
ES2178779T3 (es) 2003-01-01
ZA975439B (en) 1998-02-23
ATE223912T1 (de) 2002-09-15
DE69715439T2 (de) 2003-05-22
US20040009967A1 (en) 2004-01-15
JP2000512651A (ja) 2000-09-26
US6444823B1 (en) 2002-09-03
EP0934309B1 (en) 2002-09-11
US20040176605A1 (en) 2004-09-09
AU3342097A (en) 1998-01-07
DE19624704A1 (de) 1998-01-08
DE69715439D1 (de) 2002-10-17
JP4225571B2 (ja) 2009-02-18

Similar Documents

Publication Publication Date Title
PT934309E (pt) Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos
PT923570E (pt) Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
GB9813540D0 (en) Chemical compounds
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
MY121548A (en) Compounds and methods for the treatment of cancer
ES2169127T3 (es) Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco.
MY124122A (en) Heterocyclic derivatives
TR199901905T2 (xx) 2-(P�rin-9-il)-tetrahidrofuran-3,4-diol t�revleri.
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
HUT34746A (en) Process for the production of 2-pyrimidinil-1-piperazine-derivatives and of medical preparations containing them as agent
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200401365A1 (ru) Способы лечения илеуса
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE69830855D1 (de) Aryl-substituierte pyridylalkan-, alken-, und alkin- carboxamidderivate, verwendbar als zytostatische und immunosuppressive mittel
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
ATE188873T1 (de) Tris-platin-komplexe
ES8200094A1 (es) Procedimiento para la obtencion de alquilureas
DE60225155D1 (de) 3-substituierte 6,7-dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
TR199901385T2 (xx) Piperidin t�revleri.